<menu id="ssssw"><table id="ssssw"></table></menu>
  • <rt id="ssssw"><samp id="ssssw"></samp></rt>
  • <bdo id="ssssw"></bdo>
  • Your Good Partner in Biology Research

    BCL2L1 Antibody

    Datasheet
    • 货号:
      CSB-PA000986
    • 规格:
      ¥1320
    • 图片:
      • Western Blot analysis of 293 cells using Bcl-x Polyclonal Antibody
      • Western Blot analysis of RAT-MUSCLE cells using Bcl-x Polyclonal Antibody
    • 其他:

    产品详情

    • Uniprot No.:
    • 基因名:
      BCL2L1
    • 别名:
      Apoptosis regulator Bcl X antibody; Apoptosis regulator Bcl-X antibody; Apoptosis regulator BclX antibody; B cell lymphoma 2 like antibody; B2CL1_HUMAN antibody; Bcl 2 like 1 protein antibody; Bcl X antibody; Bcl xL antibody; BCL XL/S antibody; Bcl xS antibody; Bcl-2-like protein 1 antibody; Bcl2 Like 1 antibody; Bcl2 related gene antibody; Bcl2-L-1 antibody; BCL2L antibody; Bcl2l1 antibody; BCLX antibody; BclXL antibody; BclXs antibody; DKFZp781P2092 antibody; PPP1R52 antibody; Protein phosphatase 1 regulatory subunit 52 antibody
    • 宿主:
      Rabbit
    • 反应种属:
      Human,Mouse,Rat
    • 免疫原:
      Synthesized peptide derived from Human Bcl-x around the non-phosphorylation site of T47.
    • 免疫原种属:
      Homo sapiens (Human)
    • 标记方式:
      Non-conjugated
    • 抗体亚型:
      IgG
    • 纯化方式:
      The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
    • 浓度:
      It differs from different batches. Please contact us to confirm it.
    • 保存缓冲液:
      Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
    • 产品提供形式:
      Liquid
    • 应用范围:
      WB, IHC, IF, ELISA
    • 推荐稀释比:
      Application Recommended Dilution
      WB 1:500-1:2000
      IHC 1:100-1:300
      IF 1:200-1:1000
      ELISA 1:5000
    • Protocols:
    • 储存条件:
      Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
    • 货期:
      Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

    产品评价

    靶点详情

    • 功能:
      Potent inhibitor of cell death. Inhibits activation of caspases. Appears to regulate cell death by blocking the voltage-dependent anion channel (VDAC) by binding to it and preventing the release of the caspase activator, CYC1, from the mitochondrial membrane. Also acts as a regulator of G2 checkpoint and progression to cytokinesis during mitosis.; Isoform Bcl-X(L) also regulates presynaptic plasticity, including neurotransmitter release and recovery, number of axonal mitochondria as well as size and number of synaptic vesicle clusters. During synaptic stimulation, increases ATP availability from mitochondria through regulation of mitochondrial membrane ATP synthase F(1)F(0) activity and regulates endocytic vesicle retrieval in hippocampal neurons through association with DMN1L and stimulation of its GTPase activity in synaptic vesicles. May attenuate inflammation impairing NLRP1-inflammasome activation, hence CASP1 activation and IL1B release.; Isoform Bcl-X(S) promotes apoptosis.
    • 基因功能参考文献:
      1. Study shows that multiple ion transporters mediate the rise in pH that increases the rate of Bcl-xL deamidation in response to DNA damage in certain cells. Additionally, deamidation of Bcl-xL is intramolecularly catalyzed in a manner that is dependent upon two conserved histidines near each of the deamidation sites and that they may function together as a pH-sensitive switch. PMID: 29694915
      2. hTERT contains a BH3-like motif, a short peptide sequence found in BCL-2 family proteins, and interacts with anti-apoptotic BCL-2 family proteins MCL-1 and BCL-xL PMID: 29937479
      3. Study demonstrated that lncRNA-HEIH regulates miR-939 expression through transcriptional repression of Bcl-xL promoting colorectal tumorigenesis. PMID: 29081216
      4. Results showed that the expressions of RIP2 and BclxL were positively correlated with the malignant grade of astrocytoma. RIP2 promoted human glioblastoma cell proliferation by inducing expression of BclxL. PMID: 29693188
      5. BCL-XL has a role in modulating RAS signalling to favor breast cancer cell stemness PMID: 29066722
      6. Bcl-xL degradation during endoplasmic reticulum stress-induced apoptosis is mediated by RNF183.RNF183 ubiquitinates Bcl-xL. PMID: 29507230
      7. BCL-XL promotes stemness and contributes to the aggressiveness of both melanoma and glioblastoma. PMID: 29238043
      8. inhibition of the BCL2 family member BCLxL resulted in nanomolar potency against human synovial sarcoma cell lines and 50% tumor reduction in a genetically engineered mouse model PMID: 28851813
      9. inhibition of Bcl-xL induces significantly more apoptosis in IDH1-mutated cells than in wild-type IDH1 cells. PMID: 29057925
      10. CCAT1 is upregulated in docetaxel-resistant lung adenocarcinoma cells; its oncogenic function depends on sponging of let-7c, which releases Bcl-xl, promoting the acquisition of chemoresistance and epithelial-to-mesenchymal transition phenotypes PMID: 27566568
      11. In the epithelial ovarian cancer stem cells, 40% knock-down of Bclxl expression was sufficient to induce the full activation of caspases. Bclxl expression levels in EOC cells is dynamic and can be regulated by microenvironments that are enriched with the pro-inflammatory cytokine IL-6 such as the cancer stem cell and adipocyte niches. PMID: 28012060
      12. Study reports the interaction of BCL-XL with RASSF6. BCL-XL inhibits the interaction between RASSF6 and MDM2 and suppresses p53 expression. Consequently, BCL-XL antagonizes RASSF6-mediated apoptosis. Thus, the inhibition of RASSF6-mediated apoptosis also underlies the prosurvival role of BCL-XL. PMID: 29193479
      13. These results show that mRNA expression in centenarians is unique and reveals that Bcl-xL plays an important role in exceptional aging. PMID: 27794564
      14. that Ubiquitin-specific peptidase 18 directly bind to BCL2L1 and positively regulated its expression in hepatocellular carcinoma cells PMID: 28709980
      15. High BCL-XL expression is associated with breast cancer. PMID: 28223545
      16. The the expression of the full-length, wildtype form of PRMT2 promotes an increase in the BCL-X(L)/BCL-X(s) ratio in TNF-alpha or LPS stimulated cells. PMID: 28057797
      17. Bcl-xL is a driver in colorectal tumorigenesis and cancer progression. PMID: 27537525
      18. These data show that Mcl-1 is dispensable for the regulation of apoptosis during infection with different large DNA viruses.Bcl-XL, on the other hand, can be important to maintain survival of virus-infected cells PMID: 27537523
      19. BC200 knockout suppresses tumor cell growth in vitro and in vivo by expression of the pro-apoptotic Bcl-xS isoform. PMID: 27277684
      20. Bcl-xL inhibits GAS-induced autophagy directly by suppressing autophagosome-lysosome fusion and indirectly by suppressing GAS internalization via interaction with Beclin 1-UVRAG. PMID: 28085926
      21. The combination of 2-deoxyglucose (2-DG) and ABT-199 initiated cell death through the reduction of myeloid cell leukemia sequence 1 protein (Mcl-1) expression and c-Jun N-terminal kinase 1 (JNK1) activation and subsequent Bcl-xL protein degradation. PMID: 28038464
      22. Bcl-xL is an exosomal caspase-3 substrate and that this processing is required for the uptake of exosomes by recipient cells. PMID: 27742710
      23. dynamic Bcl-xL(S49) and (S62) phosphorylation/dephosphorylation cycles are important in the maintenance of chromosome integrity during mitosis in normal cells PMID: 27398719
      24. Mono treatment with lexatumumab was not sufficient to induce apoptosis in pancreatic cancer cells, whereas focal adhesion kinase inhibitor PF573228 significantly sensitized lexatumumab-induced apoptosis. Western blotting analysis revealed that lexatumumab and PF573228 combination treatment increased death receptor 5 but decreased Bcl-xL expression. PMID: 28459212
      25. Reduced lifetimes of the donor were partially restored by coexpression of HIF-1alpha or Bcl-xL, binding proteins of IPAS in the nucleus and mitochondria, respectively. PMID: 28003430
      26. mechanistic studies, inhibition of SRC and PKCdelta completely ablated the ability of MDA-7/IL-24 to reduce the Bcl-x(L)/(s) mRNA ratio and cell viability. These findings show that Bcl-x(s) expression is an important mediator of MDA-7/IL-24-induced cytotoxicity requiring the SRC/PKCdelta signaling axis in NSCLC cells. PMID: 27519412
      27. Resistance induced in newly formed cancer stem cells is mediated by the anti-apoptotic molecule BCL-XL and inhibition of BCL-XL with the BH3 mimetic ABT-737 sensitizes these cancer cells toward chemotherapy. PMID: 25483065
      28. we discovered that deletions involving the PARK2 gene are significantly anti-correlated with focal amplifications of the gene encoding BCL-XL. PMID: 28038320
      29. The C-terminal tail of BCL-XL forms a membrane-embedded alpha-helix that anchors the protein's globular head to the lipid bilayer membrane, yet retains a significant degree of conformational dynamics. PMID: 26923059
      30. Bcl-xL overexpression may be closely related to the dynamic of the pathogenesis and development of tongue carcinoma. PMID: 25550772
      31. Results provide evidence that microRNA 421 induces apoptosis of cervical cancer cells via down-regulation of Bcl-xL. PMID: 27886335
      32. We conclude that Bcl-x plays a role in regulation of HSC apoptosis and modulation of Bcl-x alternative splicing may become a novel molecular therapy for liver fibrosis. PMID: 27579319
      33. Intracellular expression of Bcl-xL was significantly greater in CD4+ T-cells, CD8+ T-cells, and NK cells of infants with bronchiolitis compared to controls. PMID: 26541527
      34. Data indicate the potential of functionalized Apt-carbon nanotubes conjugates for increasing the induction of apoptosis in Mucin-1 (MUC1) positive tumor cells by suppression of Bcl-xL transcript. PMID: 26731195
      35. Genetic and pharmacological inhibition of BCL-W and BCL-XL causes directed elimination of senescent cells. PMID: 27048913
      36. miR-133a and miR-326 downregulate the mRNA expression of Bcl-xl in HepG2 cells. PMID: 26239225
      37. Bcl-xL is a key factor in polyploidization resistance in acute myeloid leukemia PMID: 26188358
      38. This study lends new molecular insights into understanding the binding specificity of BH3 ligands to BclXL with important consequences on the design of novel anticancer drugs. PMID: 24114183
      39. TCERG1 sensitizes a cell to apoptotic agents, thus promoting apoptosis by regulating the alternative splicing of both the Bcl-x and Fas/CD95 genes. PMID: 26462236
      40. Data show that JAK/STAT signaling inhibition is potentiated by Bcl-xL (B-cell lymphoma-extra large) blockade in interleukin 2 (IL-2) dependent adult T-cell leukemia cells. PMID: 26396258
      41. Data suggest BCL2-like 1 protein (BCL2L1) and deleted in liver cancer 1 protein (DLC1) as potential druggable targets for specific subsets of gastric cancer (GC) cases. PMID: 26401016
      42. CD40 signaling led to sustained ERK1/2 activation and up-regulation of Bcl-xL in BCR-primed HF1A3 germinal center B cells.[BCR] PMID: 26054744
      43. miR-326 targets antiapoptotic Bcl-xL and mediates apoptosis in human platelets. PMID: 25875481
      44. alpha4 is an important regulatory molecule of apoptosis and Bcl-xL phosphorylation induced by BCR crosslinking. PMID: 25876659
      45. These findings suggested that Bcl-xL may be a promising therapeutic approach for the treatment of NSCLC PMID: 25683634
      46. Weakening the inhibition of either Bax or ceramide channels decreased the ability of Bcl-xL to protect cells from apoptosis in a stimulus-dependent manner. PMID: 26215742
      47. BCL-XL up-regulation by STAT3 contributes to mutant KRAS-mediated apoptosis resistance. Such resistance can be overcome by potent BIM induction and concurrent BCL-XL antagonism PMID: 26245900
      48. BCL2L1 mutation mediates copy number variant 20q11.21 in hESC lines. PMID: 24286026
      49. We conclude that enhanced Bcl-xL levels confer resistance to cells upon epithelial to mesenchymal transformation PMID: 25473892
      50. the combination of simultaneous siRNA-mediated knockdown of antiapoptotic Bcl-xL and survivin-a multitarget molecular-based therapy-and conventional chemotherapy shows great potential for improving bladder cancer treatment. PMID: 23749114

      显示更多

      收起更多

    • 亚细胞定位:
      [Isoform Bcl-X(L)]: Mitochondrion inner membrane. Mitochondrion outer membrane. Mitochondrion matrix. Cytoplasmic vesicle, secretory vesicle, synaptic vesicle membrane. Cytoplasm, cytosol. Cytoplasm, cytoskeleton, microtubule organizing center, centrosome. Nucleus membrane; Single-pass membrane protein; Cytoplasmic side.
    • 蛋白家族:
      Bcl-2 family
    • 组织特异性:
      Bcl-X(S) is expressed at high levels in cells that undergo a high rate of turnover, such as developing lymphocytes. In contrast, Bcl-X(L) is found in tissues containing long-lived postmitotic cells, such as adult brain.
    • 数据库链接:

      HGNC: 992

      OMIM: 600039

      KEGG: hsa:598

      STRING: 9606.ENSP00000302564

      UniGene: Hs.516966



    1v1周青梅郑宣木天寥
    <menu id="ssssw"><table id="ssssw"></table></menu>
  • <rt id="ssssw"><samp id="ssssw"></samp></rt>
  • <bdo id="ssssw"></bdo>